When acute myeloid leukemia m2 is cured, long-term survival is usually achieved. A progression-free survival of more than five years is clinically referred to as a cure. Acute myeloid leukemia M2 is the most common subtype of acute myeloid leukemia and is primarily a lesion with abnormalities of primitive and naïve myeloid cells in the bone marrow and peripheral blood. Patients are controlled by conventional chemotherapy (cytarabine and flexerodine), and a progression-free survival of more than five years can be termed clinically cured. Acute myeloid leukemia type M2 can be treated with chemotherapy and bone marrow transplantation to effectively control the disease, inhibit the growth of cancer cells, and prolong survival. It is suggested that after acute myeloid leukemia type M2 is cured, regular review must be conducted to prevent complications. The use of drugs should be under the guidance of physicians.